Chile · Delayed Price · Currency is CLP Revance Therapeutics Statistics
Total Valuation
SNSE:ECL has a market cap or net worth of CLP 1.30 trillion. The enterprise value is 3.20 trillion.
| Market Cap | 1.30T |
| Enterprise Value | 3.20T |
Important Dates
The last earnings date was Friday, July 25, 2025.
| Earnings Date | Jul 25, 2025 |
| Ex-Dividend Date | May 23, 2025 |
Share Statistics
SNSE:ECL has 1.05 billion shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 1.05B |
| Shares Outstanding | 1.05B |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 17.44% |
| Float | 421.39M |
Valuation Ratios
The trailing PE ratio is 5.30 and the forward PE ratio is 6.56.
| PE Ratio | 5.30 |
| Forward PE | 6.56 |
| PS Ratio | 0.70 |
| PB Ratio | 0.80 |
| P/TBV Ratio | 0.80 |
| P/FCF Ratio | 6.04 |
| P/OCF Ratio | 1.57 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.90, with an EV/FCF ratio of 14.88.
| EV / Earnings | 13.05 |
| EV / Sales | 1.72 |
| EV / EBITDA | 5.90 |
| EV / EBIT | 7.87 |
| EV / FCF | 14.88 |
Financial Position
The company has a current ratio of 2.09, with a Debt / Equity ratio of 1.35.
| Current Ratio | 2.09 |
| Quick Ratio | 1.37 |
| Debt / Equity | 1.35 |
| Debt / EBITDA | 4.11 |
| Debt / FCF | 10.27 |
| Interest Coverage | 3.38 |
Financial Efficiency
Return on equity (ROE) is 15.96% and return on invested capital (ROIC) is 6.60%.
| Return on Equity (ROE) | 15.96% |
| Return on Assets (ROA) | 5.84% |
| Return on Invested Capital (ROIC) | 6.60% |
| Return on Capital Employed (ROCE) | 10.12% |
| Revenue Per Employee | 1.70B |
| Profits Per Employee | 223.54M |
| Employee Count | 1,097 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 9.91 |
Taxes
In the past 12 months, SNSE:ECL has paid 85.61 billion in taxes.
| Income Tax | 85.61B |
| Effective Tax Rate | 25.88% |
Stock Price Statistics
The stock price has increased by +41.72% in the last 52 weeks. The beta is 0.08, so SNSE:ECL's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | +41.72% |
| 50-Day Moving Average | 1,239.23 |
| 200-Day Moving Average | 1,054.07 |
| Relative Strength Index (RSI) | 56.18 |
| Average Volume (20 Days) | 928,075 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SNSE:ECL had revenue of CLP 1.86 trillion and earned 245.22 billion in profits. Earnings per share was 232.64.
| Revenue | 1.86T |
| Gross Profit | 438.48B |
| Operating Income | 401.64B |
| Pretax Income | 330.83B |
| Net Income | 245.22B |
| EBITDA | 533.92B |
| EBIT | 401.64B |
| Earnings Per Share (EPS) | 232.64 |
Balance Sheet
The company has 307.26 billion in cash and 2.21 trillion in debt, giving a net cash position of -1,901.86 billion or -1,805.60 per share.
| Cash & Cash Equivalents | 307.26B |
| Total Debt | 2.21T |
| Net Cash | -1,901.86B |
| Net Cash Per Share | -1,805.60 |
| Equity (Book Value) | 1.63T |
| Book Value Per Share | 1,549.53 |
| Working Capital | 456.84B |
Cash Flow
In the last 12 months, operating cash flow was 825.30 billion and capital expenditures -610.26 billion, giving a free cash flow of 215.04 billion.
| Operating Cash Flow | 825.30B |
| Capital Expenditures | -610.26B |
| Free Cash Flow | 215.04B |
| FCF Per Share | 204.16 |
Margins
Gross margin is 23.54%, with operating and profit margins of 21.56% and 13.16%.
| Gross Margin | 23.54% |
| Operating Margin | 21.56% |
| Pretax Margin | 17.76% |
| Profit Margin | 13.16% |
| EBITDA Margin | 28.66% |
| EBIT Margin | 21.56% |
| FCF Margin | 11.54% |
Dividends & Yields
This stock pays an annual dividend of 50.13, which amounts to a dividend yield of 4.14%.
| Dividend Per Share | 50.13 |
| Dividend Yield | 4.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.07% |
| Shareholder Yield | 4.07% |
| Earnings Yield | 18.88% |
| FCF Yield | 16.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |